Suppr超能文献

YAP/BRD4 调控的 ROR1 促进胰腺癌肿瘤起始细胞和过度增殖。

YAP/BRD4-controlled ROR1 promotes tumor-initiating cells and hyperproliferation in pancreatic cancer.

机构信息

Department of Medical Biochemistry, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.

Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, Japan.

出版信息

EMBO J. 2023 Jul 17;42(14):e112614. doi: 10.15252/embj.2022112614. Epub 2023 Apr 25.

Abstract

Tumor-initiating cells are major drivers of chemoresistance and attractive targets for cancer therapy, however, their identity in human pancreatic ductal adenocarcinoma (PDAC) and the key molecules underlying their traits remain poorly understood. Here, we show that a cellular subpopulation with partial epithelial-mesenchymal transition (EMT)-like signature marked by high expression of receptor tyrosine kinase-like orphan receptor 1 (ROR1) is the origin of heterogeneous tumor cells in PDAC. We demonstrate that ROR1 depletion suppresses tumor growth, recurrence after chemotherapy, and metastasis. Mechanistically, ROR1 induces the expression of Aurora kinase B (AURKB) by activating E2F through c-Myc to enhance PDAC proliferation. Furthermore, epigenomic analyses reveal that ROR1 is transcriptionally dependent on YAP/BRD4 binding at the enhancer region, and targeting this pathway reduces ROR1 expression and prevents PDAC growth. Collectively, our findings reveal a critical role for ROR1high cells as tumor-initiating cells and the functional importance of ROR1 in PDAC progression, thereby highlighting its therapeutic targetability.

摘要

肿瘤起始细胞是化疗耐药的主要驱动因素,也是癌症治疗的有吸引力的靶点,然而,它们在人类胰腺导管腺癌 (PDAC) 中的身份以及它们特征背后的关键分子仍知之甚少。在这里,我们表明,具有部分上皮-间充质转化 (EMT) 样特征的细胞亚群,其特征是高表达受体酪氨酸激酶样孤儿受体 1 (ROR1),是 PDAC 中异质性肿瘤细胞的起源。我们证明 ROR1 的耗竭可抑制肿瘤生长、化疗后复发和转移。在机制上,ROR1 通过 c-Myc 激活 E2F 诱导 Aurora 激酶 B (AURKB) 的表达,从而增强 PDAC 的增殖。此外,表观基因组分析表明,ROR1 的转录依赖于 YAP/BRD4 在增强子区域的结合,靶向该途径可降低 ROR1 的表达并阻止 PDAC 的生长。总的来说,我们的研究结果揭示了 ROR1high 细胞作为肿瘤起始细胞的关键作用,以及 ROR1 在 PDAC 进展中的功能重要性,从而突出了其治疗靶点的可靶向性。

相似文献

1
YAP/BRD4-controlled ROR1 promotes tumor-initiating cells and hyperproliferation in pancreatic cancer.
EMBO J. 2023 Jul 17;42(14):e112614. doi: 10.15252/embj.2022112614. Epub 2023 Apr 25.
2
Role of Wnt5b-Ror1 signaling in the proliferation of pancreatic ductal adenocarcinoma cells.
Genes Cells. 2024 Jun;29(6):503-511. doi: 10.1111/gtc.13115. Epub 2024 Mar 26.
3
SETD8 induces stemness and epithelial-mesenchymal transition of pancreatic cancer cells by regulating ROR1 expression.
Acta Biochim Biophys Sin (Shanghai). 2021 Dec 8;53(12):1614-1624. doi: 10.1093/abbs/gmab140.
4
Twist promotes tumor metastasis in basal-like breast cancer by transcriptionally upregulating ROR1.
Theranostics. 2018 Apr 9;8(10):2739-2751. doi: 10.7150/thno.21477. eCollection 2018.
5
The Role of ROR1 in Chemoresistance and EMT in Endometrial Cancer Cells.
Medicina (Kaunas). 2023 May 21;59(5):994. doi: 10.3390/medicina59050994.
6
ROR1 is highly expressed in circulating tumor cells and promotes invasion of pancreatic cancer.
Mol Med Rep. 2018 Dec;18(6):5087-5094. doi: 10.3892/mmr.2018.9500. Epub 2018 Sep 20.
8
Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.
Cancer Res. 2013 Jun 15;73(12):3649-60. doi: 10.1158/0008-5472.CAN-12-3832.
9
ROR1 and ROR2 expression in pancreatic cancer.
BMC Cancer. 2021 Nov 11;21(1):1199. doi: 10.1186/s12885-021-08952-9.

引用本文的文献

1
The Role of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Cancer Stem Cell Signaling.
Int J Mol Sci. 2025 Aug 13;26(16):7828. doi: 10.3390/ijms26167828.
2
Unveiling CTRB2, RSPO3, KLOTB, and ROR1 as obesity-pancreatic disease association proteins: a comprehensive Mendelian randomization study.
Gastroenterol Rep (Oxf). 2025 Jul 31;13:goaf057. doi: 10.1093/gastro/goaf057. eCollection 2025.
3
Plasma Proteomic Profiling Reveals Distinct Signatures of Chest CT Phenotypes in Sarcoidosis.
bioRxiv. 2025 Jun 25:2025.06.24.661339. doi: 10.1101/2025.06.24.661339.
4
VCPIP1 facilitates pancreatic adenocarcinoma progression via Hippo/YAP signaling.
Cell Death Dis. 2025 May 28;16(1):422. doi: 10.1038/s41419-025-07746-2.
6
Unlocking the potential: advancements and future horizons in ROR1-targeted cancer therapies.
Sci China Life Sci. 2024 Dec;67(12):2603-2616. doi: 10.1007/s11427-024-2685-9. Epub 2024 Aug 12.
9
Variant Transcript of ROR1 ENST00000545203 Does Not Encode ROR1 Protein.
Biomedicines. 2024 Jul 16;12(7):1573. doi: 10.3390/biomedicines12071573.
10
Exosomal ROR1 in peritoneal fluid identifies peritoneal disseminated PDAC and is associated with poor survival.
Front Immunol. 2024 May 23;15:1253072. doi: 10.3389/fimmu.2024.1253072. eCollection 2024.

本文引用的文献

1
KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge.
Cell Discov. 2022 Jan 25;8(1):5. doi: 10.1038/s41421-021-00368-w.
2
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS Inhibitor.
J Med Chem. 2022 Feb 24;65(4):3123-3133. doi: 10.1021/acs.jmedchem.1c01688. Epub 2021 Dec 10.
3
Development of a DELFIA method to detect oncofetal antigen ROR1-positive exosomes.
Biochem Biophys Res Commun. 2021 Nov 12;578:170-176. doi: 10.1016/j.bbrc.2021.08.054. Epub 2021 Aug 24.
4
Acquired Resistance to KRAS Inhibition in Cancer.
N Engl J Med. 2021 Jun 24;384(25):2382-2393. doi: 10.1056/NEJMoa2105281.
5
Cancer stem cell-immune cell crosstalk in tumour progression.
Nat Rev Cancer. 2021 Aug;21(8):526-536. doi: 10.1038/s41568-021-00366-w. Epub 2021 Jun 8.
7
Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis.
Nature. 2021 Jan;589(7842):448-455. doi: 10.1038/s41586-020-03046-1. Epub 2020 Dec 16.
8
Pancreatic cancer.
Lancet. 2020 Jun 27;395(10242):2008-2020. doi: 10.1016/S0140-6736(20)30974-0.
9
LGR5 marks targetable tumor-initiating cells in mouse liver cancer.
Nat Commun. 2020 Apr 23;11(1):1961. doi: 10.1038/s41467-020-15846-0.
10
Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance.
Cancer Cell. 2020 Apr 13;37(4):471-484. doi: 10.1016/j.ccell.2020.03.007.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验